Medication info
Eurogaba Capsule 150 mg (Pregabalin)

Eurogaba Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Yuyu Pharmaceutical Co., Ltd.
Appearance
A hard capsule with white upper and lower parts containing white powder.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201701473 · Approved 2017.03.28 · Insurance code 644502370

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as the total daily dose of pregabalin divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: An initial dose of 150 mg per day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: An initial dose of 150 mg per day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: An initial dose of 150 mg per day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and may be increased within 1 week to 150 mg twice daily (300 mg per day), based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Although clinical studies were also conducted at a dose of 600 mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr) ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr) ≥30-<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr) ≥15-<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr) <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to a dose administered once in addition. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended. Adolescents aged 12-17 years: Administration is not recommended.

Ingredients

Manufacturer
Yuyu Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used in adults to treat peripheral and central neuropathic pain. It is also effective as an adjunctive treatment for partial seizures in patients with epilepsy, whether or not they have secondary general symptoms. Additionally, it aids in improving symptoms of fibromyalgia. This medication is utilized for various neurological conditions and pain management.

How to take

Adult dose

This medicine is administered orally as the total daily dose of pregabalin divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: An initial dose of 150 mg per day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: An initial dose of 150 mg per day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: An initial dose of 150 mg per day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and may be increased within 1 week to 150 mg twice daily (300 mg per day), based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Although clinical studies were also conducted at a dose of 600 mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr) ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr) ≥30-<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr) ≥15-<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr) <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to a dose administered once in addition. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended. Adolescents aged 12-17 years: Administration is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, if symptoms of depression or mood changes occur during treatment, medical staff must be informed immediately. This medication should not be taken by individuals with hypersensitivity to this drug or certain genetic problems such as lactose intolerance. Patients with diabetes may experience effects on blood sugar control due to weight gain, and adjustments to diabetes medication may be necessary. If symptoms of angioedema appear, the medication should be stopped immediately. Elderly patients should be careful due to risks of dizziness or drowsiness that can lead to falls. Visual disturbances or changes in sight may occur, and if symptoms appear, consultation with medical staff is necessary. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so dosage should be gradually reduced under physician's guidance. Patients with a history of substance abuse should be carefully monitored as the risk of abuse of this medication may be higher. In patients with heart disease, careful use is advised, particularly when taken with opioid analgesics due to risks of central nervous system depression. There may be a risk of respiratory depression; therefore, dose adjustments may be required in patients with respiratory or neurological diseases and in elderly patients. In early pregnancy, there is a risk of fetal malformations; thus, pregnant women should avoid this medication, and women of childbearing age should use effective contraception. During breastfeeding, this medication can be passed into breast milk and may affect infants, so consideration should be given to either stopping breastfeeding or discontinuing the medication. There is a risk of accidents while driving or operating machinery due to dizziness or drowsiness; caution is advised. Severe skin reactions can occur rarely, and if symptoms such as rashes or swelling develop, the medication should be stopped immediately, and medical consultation is required. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatments such as hemodialysis may be necessary. This medication should be kept out of the reach of children and should not be transferred to another container.

Side effects

  • suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 178 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • sadness
  • suicidal ideas
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of inhibition
  • apathy
  • ataxia
  • motor coordination disorders
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensation loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reduced reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing disorders
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • bradycardia
  • tachyarrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distention
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux disease
  • reduced oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • abnormal sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • reduced serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • agitation
  • restlessness
  • exacerbation of seizures
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air or moisture, and it is recommended to store it at room temperature between 15 degrees and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness and prevent degradation.

Appearance and packaging

Appearance

A hard capsule with white upper and lower parts containing white powder.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.